BIO-B Stock — Bio-Rad Laboratories Inc

Bio-Rad Laboratories Inc (BIO-B)

Updated October 14, 2026.

BIO-B is a Stock. Total return is 16706.7% over the past 41.9 years.

Bio-Rad Laboratories develops, manufactures, and distributes life science research instruments and clinical diagnostic products used in hospitals, laboratories, pharmaceutical manufacturing, and academic research across the world. The company operates two segments: Life Science, which provides equipment and reagents for biological analysis and biopharmaceutical applications, and Clinical Diagnostics, which supplies diagnostic testing systems and quality control products for clinical laboratories and physician offices. The company does not currently have an established distribution schedule.

BIO-B performance

Price and return data through 2026-10-14.

Total return is 16706.7% over the past 41.9 years. Its deepest 1-year drawdown was 20.4%.

BIO-B key facts

Asset type

Stock

Asset class

Equity

Inception date

11/05/1984

Distribution frequency

None

Last close

$364.15 (stale; as of 2026-10-14)

Market cap

$1,842,976,988

Average volume

231.0

Beta

1.068

Payout ratio

0.0%

P/E ratio

46.15

Forward P/E

39.8406

EPS

$7.89

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

BIO-B risks and drawbacks

The deepest 1-year drawdown on record here is 20.4%.

Who may consider BIO-B — and who may not

It is a weaker fit for investors who need monthly cash flow (BIO-B does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on BIO-B

• All tickers starting with B

Tagged: Healthcare.

Frequently asked questions